Harvard Bioscience (HBIO) Raw Materials (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Raw Materials data on file, last reported at $13.3 million in Q1 2026.

• Quarterly Raw Materials fell 9.09% year-over-year to $13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.3 million (down 9.09% YoY) and the FY2025 annual result came in at $12.2 million, down 20.28% from the prior year.
• Raw Materials rose to $13.3 million in Q1 2026 per HBIO's latest filing, from $12.2 million in the prior quarter.
• Across five years, Raw Materials topped out at $19.2 million in Q2 2022 and bottomed at $12.2 million in Q4 2025.
• The 5-year median for Raw Materials is $15.4 million (2023), against an average of $15.9 million.
• The widest annual swing landed in 2022, when Raw Materials soared 31.79%; it then dropped 24.1% in 2025.
• Tracing HBIO's Raw Materials over 5 years: stood at $17.4 million in 2022, then dropped by 11.65% to $15.4 million in 2023, then retreated by 0.9% to $15.3 million in 2024, then dropped by 20.28% to $12.2 million in 2025, then advanced by 9.58% to $13.3 million in 2026.
• Per Business Quant, the three latest HBIO Raw Materials figures stand at $13.3 million (Q1 2026), $12.2 million (Q4 2025), and $13.5 million (Q3 2025).

Peer Comparison